Stage 1 (Mild COPD): In this stage, airflow limitation is mild, and symptoms may be subtle. Patients may experience occasional coughing and shortness of breath, especially during physical exertion. Lung function tests show a mild decrease in airflow.
Stage 2 (Moderate COPD): Symptoms become more noticeable in stage 2, with increased coughing, wheezing, and shortness of breath, even during mild activity. Lung function tests reveal a moderate decrease in airflow.
Stage 3 (Severe COPD): In this stage, symptoms become more severe and can significantly impact daily life. Patients experience frequent coughing, wheezing, and shortness of breath, even at rest. Lung function tests show a marked decrease in airflow.
Correction of Hypoxemia: COPD frequently results in inadequate blood oxygenation, leading to hypoxemia. Oxygen concentrators deliver oxygen at higher concentrations than ambient air, effectively correcting hypoxemia and bolstering oxygen saturation levels in the bloodstream.
Alleviation of Breathlessness: Hypoxemia contributes significantly to breathlessness, particularly during physical exertion. Oxygen therapy administered via concentrators alleviates this symptom by restoring oxygen levels, thereby reducing breathlessness and enhancing the patient's capacity to engage in daily activities with reduced respiratory effort.
Support for Pulmonary Function: COPD compromises lung function, impairing the lungs' ability to extract oxygen from inhaled air. Oxygen therapy facilitated by concentrators ensures a steady oxygen supply to support vital organ function and overall pulmonary health, optimizing respiratory efficiency.